Go to Top

BIOLASE, Inc. (BIOL): Revenue Guidance in excess of $18 million

BIOLASE is specializing in the development, manufacturing and marketing of lasers and related products to provide biological treatments that eliminate pain and are safer for patients.

biol epicBIOLASE leads the global dental industry with laser systems such as the WaterLase iPlus™ and WaterLase MDX™, which both feature novel, patented laser technologies designed by BIOLASE’s R&D and clinical teams to perform dental and medical surgery, while dramatically reducing pain and improving clinical results.

BIOL announced today that, based on a preliminary review of its financial performance for the fourth quarter ended December 31, 2012, the Company expects to exceed its previous guidance and report net revenue in excess of $18 million.

We are very pleased with the strong growth in our core dental laser products and the trends that are accelerating with the adoption of our WaterLase® technology and diode laser systems. Our strong revenue growth in the 2012 fourth quarter compared to the prior year period was primarily due to the increased demand for our flagship WaterLase iPlus™ and our new EPIC 10™ soft tissue diode laser.
Federico Pignatelli, Chairman and CEO of BIOLASE

Research on BioLase

One Response to "BIOLASE, Inc. (BIOL): Revenue Guidance in excess of $18 million"